Abstract
Ultrasound contrast agents (UCA) represented by gas-filled microbubble, can provide simultaneous and co-localized enhancement on image contrast to help disease diagnosis by highlighting tissue borders. Nowadays, Some UCAs (e.g. Levovist®, Optison®, Definity®, and Sonovue®) are commercially available, and have been clinically utilized for enhanced ultrasonography in the US, Canada, Europe, Asia and so on. However, their large diameters (1~10 µm) mainly hinder more precise and deeper applications in the imaging of capillaryabundant organs or tissues (e.g. tumor), and undersized nanoscale UCAs also lack enough backscattering echo intensity to distinguish abnormal distribution of vessels. So novel shapes, structures and materials of nano-sized UCAs are constantly emerging for cancer ultrasonic imaging. Particularly, the cavitation effect of diagnostic ultrasound can accelerate effusion of loaded contents from UCAs, following cellular uptake. This will inevitably contribute to develop other potential applications of nano-sized UCAs towards cancer therapy and theranostics.
Keywords: Ultrasound contrast agents, cancer therapy, cancer theranostics, nano-sized, polymer.
Current Pharmaceutical Design
Title:Nano-sized Ultrasound Contrast Agents for Cancer Therapy and Theranostics
Volume: 23 Issue: 35
Author(s): Hao Li, Shenglong Gan, Shi-Ting Feng, Guofu Zhou, Zhi Dong, Rongqin Zheng*Zi-Ping Li*
Affiliation:
- Department of Ultrasonography, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630,China
- Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080,China
Keywords: Ultrasound contrast agents, cancer therapy, cancer theranostics, nano-sized, polymer.
Abstract: Ultrasound contrast agents (UCA) represented by gas-filled microbubble, can provide simultaneous and co-localized enhancement on image contrast to help disease diagnosis by highlighting tissue borders. Nowadays, Some UCAs (e.g. Levovist®, Optison®, Definity®, and Sonovue®) are commercially available, and have been clinically utilized for enhanced ultrasonography in the US, Canada, Europe, Asia and so on. However, their large diameters (1~10 µm) mainly hinder more precise and deeper applications in the imaging of capillaryabundant organs or tissues (e.g. tumor), and undersized nanoscale UCAs also lack enough backscattering echo intensity to distinguish abnormal distribution of vessels. So novel shapes, structures and materials of nano-sized UCAs are constantly emerging for cancer ultrasonic imaging. Particularly, the cavitation effect of diagnostic ultrasound can accelerate effusion of loaded contents from UCAs, following cellular uptake. This will inevitably contribute to develop other potential applications of nano-sized UCAs towards cancer therapy and theranostics.
Export Options
About this article
Cite this article as:
Li Hao , Gan Shenglong, Feng Shi-Ting, Zhou Guofu , Dong Zhi , Zheng Rongqin *, Li Zi-Ping*, Nano-sized Ultrasound Contrast Agents for Cancer Therapy and Theranostics, Current Pharmaceutical Design 2017; 23 (35) . https://dx.doi.org/10.2174/1381612823666170710120631
DOI https://dx.doi.org/10.2174/1381612823666170710120631 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews Alternative Medicine Safety: Agaricus blazei and Propolis
Combinatorial Chemistry & High Throughput Screening Acute Kidney Injury: Turning the Tide
Current Drug Targets Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies Association of Smoking and Alcohol Drinking with Dementia Risk Among Elderly Men in China
Current Alzheimer Research Liver-Based In Vitro Technologies for Drug Biotransformation Studies - A Review
Current Drug Metabolism Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Hyperthermia Associated Osteonecrosis in Young Patients with Pelvic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Ca2+ Mediates the Adhesion of Breast Cancer Cells in Self-Assembled Multifunctional Microfluidic Chip Prepared with Carbohydrate Beads
Micro and Nanosystems Penetration of Tumor Therapy Interesting Substances in Non-Vascularized Metastases: Review of Studies in Multicellular Spheroids
Current Cancer Therapy Reviews Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry An efficient Synthesis of New Fused Oxazinocarbazoles
Letters in Organic Chemistry Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways
Current Cancer Drug Targets MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Metastatic Thyroid Cancer Unresponsive to Conventional Therapies: Novel Management Approaches Through Translational Clinical Research
Current Drug Targets - Immune, Endocrine & Metabolic Disorders MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology New Drug Targets for Genomic Cancer Therapy Successes, Limitations, Opportunities and Future Challenges
Current Cancer Drug Targets